Oppenheimer Initiates Coverage of Harpoon Therapeutics (HARP) with Outperform Recommendation

Fintel reports that on January 5, 2024, Oppenheimer initiated coverage of Harpoon Therapeutics (NasdaqCM:HARP) with a Outperform recommendation.

admin